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Abstract
Thiocillins from Bacillus cereus ATCC 14579 are members of the well-known thiazolyl peptide 
class of natural product antibiotics, the biosynthesis of which has recently been shown to proceed 
via posttranslational modification of ribosomally encoded precursor peptides. It has long been 
hypothesized that the final step of thiazolyl peptide biosynthesis involves a formal [4 + 2] 
cycloaddition between two dehydroalanines, a unique transformation that had eluded enzymatic 
characterization. Here we demonstrate that TclM, a single enzyme from the thiocillin biosynthetic 
pathway, catalyzes this transformation. To facilitate characterization of this new class of enzyme, 
we have developed a combined chemical and biological route to the complex peptide substrate, 
relying on chemical synthesis of a modified C-terminal fragment and coupling to a 38-residue 
leader peptide by means of native chemical ligation (NCL). This strategy, combined with active 
enzyme, provides a new chemoenzymatic route to this promising class of antibiotics.
Thiazolyl peptides are a growing class of highly modified, peptide-derived natural products 
with potent activity against antibiotic resistant bacteria, including methicillin-resistant 
Staphylococcus aureus and vancomycin-resistant Enterococci. 1,2 Despite their potential 
therapeutic value, thiazolyl peptides have gone largely underdeveloped because of their 
generally poor solubility and bioavailability. Moreover, efforts to improve on these limiting 
properties by means of synthesis or chemical modification are hindered by the complex 
macrocyclic architecture of the compound class: thiazolyl peptides feature multiple azoline 
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heterocycles alternating with modified peptide side chains and cyclized on a trisubstituted 
pyridine (or piperidine) core (Figure 1).
Although a number of total syntheses have tackled the task of modified thiazolyl peptides, to 
date the most substantive improvements have come by means of semisynthetic strategies.3–7 
Researchers at Novartis installed new solubilizing functionalities at the C-terminus of 
Streptomycete-derived GE2270A, yielding LFF571, a derivative currently in phase-II 
clinical trials for treatment of Clostridium difficile.8 Nevertheless, the key central 
macrocycle, constituting the majority of the drug pharmacophore, remains largely 
intractable to semisynthesis, limiting LFF571 solubility and efficacy to infections of the 
upper gastrointestinal tract.
Thiazolyl peptides are ribosomally synthesized and posttranslationally modified peptide 
natural products (RiPPs).9 They are biosynthesized from a precursor peptide containing an 
N-terminal leader and a C-terminal core peptide motif. Knockout studies in Bacillus cereus 
ATCC 14579 have demonstrated the importance of the putative enzyme TclM in late-stage 
biosynthetic cyclization of this group of thiazolyl peptides.10–12 TclM presents a potentially 
unique enzymatic activity: the long-hypothesized formal [4 + 2] cycloaddition between two 
dehydroalanines (Dhas) to generate the substituted pyridine core of the thiocillins.13–15 This 
putative “hetero-Diels–Alderase” activity is unique from both enzymatic and purely 
synthetic standpoints. In terms of enzymology, very few such “Diels–Alderases” are known, 
let alone members effecting a heteroannulative version of the chemistry. Enzymes that have 
been characterized as potential “Diels–Alderases”16 often enhance spontaneous chemical 
cyclizations (e.g., SpnF17 and VstJ18), yet the proposed transformation of TclM is 
demonstrably nonspontaneous: Moody and co-workers have induced this chemistry on 
simple substrates by severe microwave irradiation.19 From a synthetic standpoint, TclM 
could provide a mild, late-stage route to the thiazolyl peptide core and allow access to new 
soluble derivatives. Herein we develop a combined chemical and biological strategy to 
access a leader-peptide-conjugated, doubly dehydrated substrate for TclM and demonstrate 
in vitro the ability of TclM to catalyze a formal [4 + 2] cycloaddition to form the mature 
pyridine ring.
Previous experiments in our lab suggested that the leader peptide is necessary for TclM 
modification of the putative substrate, but solid-phase peptide synthesis (SPPS) of a full 52-
residue substrate with thiazolyl and dehydroamino acid residues seemed daunting, even with 
current SPPS technology. SPPS of the full substrate would also necessitate complete 
resynthesis of C-terminal variants for structure–activity probing of TclM. We therefore 
devised a strategy involving separate preparations of the C-terminal-modified component 
and the N-terminal leader peptide (Figure 2a). The fully modified C-terminal fragment could 
be prepared by total chemical synthesis, with cysteine side chains as surrogates for the 
required dehydroalanine residues. The use of cysteine at the N-terminus of the modified 
fragment would allow coupling to an intein-derived thioester of the leader peptide via native 
chemical ligation (NCL). Upon coupling, cysteine side chains could be converted to Dhas by 
a bisalkylation/elimination protocol.20
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We chose to prepare a simplified C-terminal fragment containing all six thiazoles of the 
natural thiocillin but with alanines used in place of threonines 4 and 6 and valine 8 and an 
ethyl ester in place of the two modified threonines at the C-terminus. Previous efforts had 
indicated that TclM would be permissive to alanine substitution at these sites, although these 
analogues would likely not be antibiotically active.12 This hexathiazole precursor could be 
built by adapted protocols from previous total syntheses by Bagley, Ciufolini, and Nicolaou 
(see the Supporting Information (SI)).3–5,7,21 Although we anticipate that this route will be 
readily amenable to the solid phase, we employed a block solution-phase synthesis. The 
desired product was obtained in good yield over seven steps (longest linear sequence from 
the building blocks; see the SI) and could then be deprotected to give compound 12.
The 38-residue leader peptide was cloned into vector pETXSH (P. Loll lab) containing a C-
terminally His6-tagged Mycobacterium xenopi intein.22 This could be expressed and purified 
by Ni affinity chromatography and cleaved to afford the 2-mercaptoethanesulfonate (Mesna) 
thioester. Subtractive purification gave the pure thioester, which was buffer-exchanged and 
coupled to an excess of hexathiazole 12. Elimination to give compound 16 could be carried 
out under conditions published by Davis and co-workers.20 The structure of the final 
precursor was confirmed by LC/MS (Figure 2c) and rigorously characterized by MS/MS 
fragmentation (see the SI).
To evaluate the ability of TclM to effect the formal [4 + 2] cycloaddition of the two Dhas, 
the tclM gene was amplified from genomic DNA isolated from B. cereus ATCC 14579 and 
subcloned for translation as the N-terminal His6MBP-tagged fusion protein. Soluble protein 
was obtained in over 90% purity after Ni-NTA affinity and size-exclusion chromatography 
followed by tobacco etch virus (TEV) cleavage of the tag (Figure 3a and the SI). Although 
TclM does not have any obvious predicted cofactor binding pocket, we note that the purified 
protein did not appear to have any unusual absorbance in the visible-light range. Assays for 
the putative cycloaddition were conducted in a HEPES buffer at pH 7.2 and room 
temperature. Time points were taken at 4 h intervals and analyzed by high-resolution QTOF 
LC/MS and UV–vis (Figure 3b and the SI). Over course of the reaction, a new peak grew in 
at 350 nm, consistent with the known, distinctive absorbance of the trisubstituted pyridine 
core in the thiazolyl peptides.
At 20 h, all of the starting material 16 was consumed in the presence of TclM, and the new 
peak at 350 nm ceased to increase. The observed peak at m/z 962.1171 matches within 
instrumental error the value for [M + H+] of expected product 17 (m/z 962.1118) and 
exhibits the distinctive MS/MS fragmentation pattern of thiazolyl peptides (see the SI).11 
We further scaled up the enzymatic reaction and were able to isolate milligram quantities of 
product under unoptimized conditions to facilitate complete characterization via two-
dimensional NMR spectroscopy. For example, signals representing the newly formed 
pyridine protons can be clearly seen in the aromatic region, confirming the formation of the 
trithiazolylpyridine core (Figure 3d and the SI). This compound was absent from all 
controls, including those with heat-denatured enzyme or prolonged (multiple days) solution 
without enzyme.
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A potential mechanism for the TclM reaction is illustrated in Figure 4. As drawn, the 
reaction involves concerted cyclization via a stabilized tautomer of the amide carbonyl 
(imidic acid tautomer). Alternatively, the mechanism could proceed in a stepwise manner, 
allowing nucleophilic attack from a stabilized α-carbanion of the formal 2π component into 
an imidocarbonyl intermediate. Regardless of the mechanism, stepwise or concerted, to 
arrive at the final product, the putative cyclic intermediate would have to undergo 
aromatization by elimination of water and/or the leader peptide carboxamide; both steps 
may be spontaneous. We searched LC/MS traces for peaks that could represent any putative 
intermediates but found none of the anticipated masses, suggesting that either these 
intermediates are short-lived or else TclM itself catalyzes the aromatization.
This work provides direct evidence of the key role of TclM in the formal [4 + 2] 
cycloaddition to form the trithiazolylpyridine core of the thiocillins and most thiazolyl 
peptides. Our work further represents the first functional characterization of a member of 
this new class of enzymes. TclM and its homologues are remarkable in that they show little 
or no homology to members of other known enzyme classes. Even between members of the 
family, homology is low (14/31% identity/similarity to the nearest homologue, TsrE).10 
Remarkably, TclM is capable of carrying out the formal addition by itself, without accessory 
proteins or cofactors.
In conclusion, we have demonstrated that TclM catalyzes the formation of the trisubstituted 
pyridine core of an artificial thiazolyl peptide from a leader-peptide-bound substrate. 
Mechanistically, the reaction can be drawn as a formal [4 + 2] cycloaddition between two 
Dhas with subsequent aromatization, but the exact mechanism, whether stepwise or 
concerted, is still undetermined. Substrate specificity and enzyme efficiency as well as a 
detailed mechanistic understanding of this new class of enzymes are subjects of ongoing 
efforts in our lab. We have also demonstrated a chemoenzymatic route to this attractive class 
of natural products; we anticipate that this route will allow the preparation of new and 
improved analogues that are not accessible by synthetic or semisynthetic methods.
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(a) Biosynthesis of thiocillins from a modified peptide. LP = leader peptide. (b) Thiocillin 
gene cluster from Bacillus cereus ATCC 14579. Open reading frames encoding key post-
translational enzymes are shown. (c) Sequence of the 52-residue precursor featuring a 38-
residue leader sequence (gray) and a 14-residue core peptide (black).
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(a) Synthesis of the TclM substrate by thiophenol-catalyzed native chemical ligation and 
sulfhydryl elimination with dibromoadipamide. (b, c) QTOF-MS data of (b) NCL product 
15 and (c) elimination product 16.
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(a) SDS-PAGE of purified recombinant TclM. (b) Overlaid extracted ion chromatograms of 
TclM substrate and TclM assay after 20 h of incubation. The labeled peak indicates the 
newly formed thiazolyl peptide. (c) MS/MS spectrum of the isolated artificial thiazolyl 
peptide prepared by the chemoenzymatic method. Ions are labeled according to convention 
for the cyclic peptide. (d) Aromatic region of the 1H NMR spectrum showing new pyridine 
protons.
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Proposed mechanism of formal [4 + 2] cycloaddition catalyzed by TclM. The reaction may 
proceed in concerted fashion from the imidic acid, as illustrated, or else stepwise (not 
shown) to yield putative intermediate I. This undergoes further elimination/aromatization to 
the trithiazolylpyridine core of the thiocillins (structure III, R1, R2 = thiazole).
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